**Supplementary Figure 1 PRISMA flowchart.**

Supplementary Figure 2 Risk of bias assessment for randomized controlled trials.

Supplementary Figure 3 Funnel plot.

Supplementary Table 1 Search strategy

Search No.	Search strategy
#1	sofosbuvir OR "Sofosbuvir"[MeSH]
#2	velpatasvir OR "velpatasvir" [Supplementary Concept]
#3	#1 AND #2
#4	Epclusa OR "sofosbuvir-velpatasvir drug combination" [Supplementary Concept]
#5	#3 OR #4
#6	ribavirin OR "Ribavirin"[MeSH]
#7	Hepatitis C OR HCV OR "Hepatitis C"[MeSH]
#8	#5 AND #6 AND #7

The same search strategy was used for all databases.

Supplementary Table 2 Risk of bias assessment for non-randomized controlled trials

No.	Author, yr	Selection				Comparability		Outcome			Total Score	Risk of Bias (≥ 7: Low; 3-6: Moderate; < 3: High)
		Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Study control for severity of liver disease	Study control for other confounders	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts		
1	Feldon, 2018	1	1	1	1	1	0	1	1	1	8	Low
2	Wong, 2020	1	1	0	1	1	0	1	1	1	7	Low
3	Pasulo, 2019	0	0	1	1	1	0	1	1	1	6	Moderate
4	Drysdale,	1	1	1	1	0	0	1	1	0	6	Moderate

	2019										
5	Hlain g 2019	1	0	1	1	0	0	1	1	1	6	Moder ate